The emergence of oligonucleotide-based therapeutics, such as small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and therapeutic messenger RNA (mRNA), is transforming the strategies of the pharma industry and opening new avenues of research. To support this development, new and innovative ways of introducing fluorescent entities (fluorophores) to these types of modalities are needed.
Drug development projects are particularly reliant on using fluorophores that do not perturb drug-target interactions or affect affinities towards, for instance, lipid membranes or proteins, to deliver results that are representative of the performance of the corresponding unmodified drug.
This application note from Glen Research discusses applications for fluorescent base analogs in testing the performance of oligonucleotide-based therapeutics, as they mimic the native structure without introducing perturbations to biological interactions.
Offered Free by: Glen Research
See All Resources from: Glen Research